ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 4th Quarter 2023
29 Febbraio 2024 - 6:00PM
Business Wire
- 2023 consolidated revenue of €4.6 million, net of studies
for ABIONYX
- Cash position of €4.1 million as of December 31,
2023
Regulatory News:
ABIONYX Pharma, (FR0012616852 - ABNX - eligible for PEA
PME), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the
world’s only natural recombinant apoA-I, today provides an update
on its activity and cash position as of December 31, 2023.
Selected financial information (IFRS)
M€
2023
2022
Revenue from biotech activity
0.00
0.00
Revenue from IRIS Pharma
4.64
5.25
Total revenue
4.64
5.25
Other revenue
0.00
0.00
Total revenue income and
revenue
4.64
5.25
Cash and cash equivalents at the end of
the period
4.10
4.04
ABIONYX Pharma recorded a consolidated revenue of €4.64 million
for the financial year 2023 after elimination of intra-group
transactions. The subsidiary IRIS Pharma recorded an annual revenue
of €4.97 million, of which €4.06 million in preclinical and €0.91
million in clinical. Since its integration, IRIS Pharma has focused
part of its Services activity on preclinical studies of its
recombinant apoA-I, to accelerate its development in ophthalmology.
These ophthalmology studies are all proving very positive for
clinical development.
Regarding the biotech activities dedicated to the discovery and
development of innovative therapies to improve the lives of
patients, the Company did not generate any revenue in this
financial year, ABIONYX Pharma continuing to provide its bioproduct
free of charge as part of the Compassionate Access Authorization
(CAA) requests.
In addition to its available cash of €4.1 million, ABIONYX
Pharma, with the arrival in January of Dr Rob Scott as CMO and head
of R&D, is focusing on the search for strategic
partnerships.
Update on R&D activities
In the renal area, the Phase 2a clinical trial for CER-001
(RACERS) in patient with sepsis at high risk of developing acute
kidney injury, conducted in partnership with the University of
Bari, produced major positive clinical results announced last
January. The clinical study met both primary and secondary
endpoints. There is no approved treatment for sepsis, which is the
3rd leading cause of death worldwide and globally affects nearly 14
million people each year. Moreover, with an aging population, the
number of patients is expected to double by 2050.
In the orphan disease LCAT Deficiency, the Company continues to
receive and respond to new Compassionate Access Authorization
requests for CER-001 from hospitals around the world to treat
individual affected with the disease.
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines in diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated apoA-I
-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240229129925/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Grafico Azioni Abionyx Pharma (EU:ABNX)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Abionyx Pharma (EU:ABNX)
Storico
Da Apr 2023 a Apr 2024
